EUVIMEDOpdag EUVIMED
Leserbrief

Persistence of a High Seroconversion Rate 3.2 ± 0.13 Years After Last COVID‐19 Vaccination in Heart Transplant Recipients

Robin Arcani, Pierre Ambrosi iD

Clinical Transplantation · 2025

DOI: 10.1111/ctr.70190 ↗

At a glance

Leserbrief in Clinical Transplantation, 2025. Written by Robin Arcani and 1 co-authors. Institution: Laboratory of Therapeutics and the Aix-Marseille Universite, Marseille, France. Major MEDLINE topics: Antibodies, Viral, COVID-19, COVID-19 Vaccines, Heart Transplantation. Cited 1 times so far (Crossref); 5 references.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

We previously reported a high level of seroconversion 1 year after COVID‐19 vaccination in heart transplant recipients when vaccination was performed several years after transplantation. The aim of this study was to measure the seroconversion rate late after vaccination, in the absence of a new vaccine injection. We included 37 patients vaccinated in 2021. We measured immunoglobulin response using TrimericS Diasorin assay at the last visit between October 2024 and February 2025. We found a seroconversion rate of 95%, 3.2 ± 0.13 years after last COVID‐19 vaccination in the absence of new vaccine injection. Most of these patients (73%) had a proven COVID‐19 infection since vaccination. Interestingly, none of these patients had a severe form of COVID‐19. Thus, vaccination, followed by minor COVID‐19 infections, effectively prevented severe forms.

Subjects

MeSH terms (MEDLINE)

Antibodies, ViralCOVID-19COVID-19 VaccinesHeart TransplantationSARS-CoV-2SeroconversionTransplant RecipientsAdultAgedFemaleHumansMaleMiddle AgedFollow-Up StudiesVaccination

Author keywords

COVID‐19heart transplantationvaccination

Substances

Antibodies, ViralCOVID-19 Vaccines

Authors and institutions

  • Laboratory of Therapeutics and the Aix-Marseille Universite, Marseille, France.
  • Cardiac Transplant Unit, La Timone Hospital, Aix-Marseille University, Marseille, France.

ORCID profiles: Pierre Ambrosi

Cite

APA

Arcani, R., & Ambrosi, P. (2025). Persistence of a High Seroconversion Rate 3.2 ± 0.13 Years After Last COVID‐19 Vaccination in Heart Transplant Recipients. Clinical Transplantation. https://doi.org/10.1111/ctr.70190

Vancouver

Arcani R, Ambrosi P. Persistence of a High Seroconversion Rate 3.2 ± 0.13 Years After Last COVID‐19 Vaccination in Heart Transplant Recipients. Clinical Transplantation. 2025. doi:10.1111/ctr.70190

BibTeX
@article{Arcani2025,
  author = {Arcani, Robin and Ambrosi, Pierre},
  title = {Persistence of a High Seroconversion Rate 3.2 ± 0.13 Years After Last COVID‐19 Vaccination in Heart Transplant Recipients},
  journal = {Clinical Transplantation},
  year = {2025},
  doi = {10.1111/ctr.70190}
}
Start for free →